TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9894960

Group type: EXPERIMENTAL
Intervention: Hypothermic group (target temperature of 33.5 degrees C)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normothermic group (target esophageal temperature at clip application of 36.5 degrees C)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study: 8694154

Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 231

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 231
Study: 1854570

Group type: EXPERIMENTAL
Intervention: Diuretics plus enalapril or captopril (group 2)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diuretics alone (group 1)
Number of subjects: 34
Study: 6315227

Group type: EXPERIMENTAL
Intervention: Continuous chemotherapy (1‐(2‐chloroethyl‐3‐cyclohexyl‐1‐nitrosourea, cyclophosphamide, methotrexate, and vincristine followed by 4'‐demethylepipodophyllotoxin 9‐[4,6‐O‐(R) ethylidene‐beta‐D‐glucopyranoside] and doxorubicin at progression of disease)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (alternating the same drugs as continuous)
Number of subjects: 146
Study: 30557331

Group type: EXPERIMENTAL
Intervention: Computer image analysis using QCU‐CMS software
Number of subjects: 30

Group type: COMPARATOR
Intervention: Visual classification by two independent readers
Number of subjects: 30
Study: 26956618

Group type: EXPERIMENTAL
Intervention: RT3 times per week (RT3, n=20)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RT2 times per week (RT2, n=16)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (CG, n=16)
Number of subjects: 52
Study: 24576082

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Fair or poor satisfaction with primary care physician
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Not having Medicaid
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Receiving a new assistive device in the past 6 months
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Staying in a nursing home in the past 6 months
Number of subjects: 951
Study: 23046776

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) using neutral stimuli
Number of subjects: 2135

Group type: COMPARATOR
Intervention: Attention Bias Modification (ABM) using positive stimuli
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) using threat stimuli
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) using appetitive stimuli
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 2135
Study: 19409547

Group type: EXPERIMENTAL
Intervention: Müllerian inhibiting substance (MIS) assay
Number of subjects: 25
Study: 18334054

Group type: EXPERIMENTAL
Intervention: 2‐day rush induction protocol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 3‐day rush induction protocol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study: 15759946

Group type: EXPERIMENTAL
Intervention: 3 MU daily interferon (IFN)‐alpha‐2a monotherapy for 12 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6 MU daily interferon (IFN)‐alpha‐2a monotherapy for 12 months
Number of subjects: 16
Study: 12019587

Group type: EXPERIMENTAL
Intervention: Manual work
Number of subjects: 164

Group type: COMPARATOR
Intervention: Nonmanual work
Number of subjects: 164
Study: 10487369

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CHO-E)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Noncarbohydrate placebo (CON)
Number of subjects: 6
Study: 7729608

Group type: EXPERIMENTAL
Intervention: 6-h clamped hyperglycemia (PG approximately 13.5 mmol/l)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nocturnal hyperglycemia (PG approximately 13.5 mmol/l)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Euglycemia (PG approximately 5 mmol/l)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 15 h of euglycemia (approximately 5 mmol/l)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 15 h of hyperglycemia (approximately 17 mmol/l)
Number of subjects: 15
Study: 2117650

Group type: EXPERIMENTAL
Intervention: Misoprostol, 100 micrograms, four times a day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7315500

Group type: EXPERIMENTAL
Intervention: Mammary radiography screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30292850

Group type: EXPERIMENTAL
Intervention: Once-daily (OD) PCI
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Twice-daily (BD) PCI
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for patients treated with PCI
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Gross tumor volume (GTV)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Thoracic GTV (tGTV)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: ECOG performance score
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Delay between end of chemotherapy and PCI
Number of subjects: 449
Study: 29258763

Group type: EXPERIMENTAL
Intervention: 2 doses of intravenous dexamethasone and 1 dose of normal saline (Group B)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 3 doses of intravenous dexamethasone (Group C)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 3 doses of normal saline (Group A)
Number of subjects: 210
Study: 26419487

Group type: EXPERIMENTAL
Intervention: Celecoxib alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pregabalin alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pregabalin and celecoxib combination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25287827

Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib (combination therapy)
Number of subjects: 71
Study: 22186564

Group type: EXPERIMENTAL
Intervention: Dressing removed on postoperative day 1
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dressing removed on postoperative day 6
Number of subjects: 70
Study: 20975764

Group type: EXPERIMENTAL
Intervention: Group X (change from isoflurane to desflurane)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Group D (desflurane)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Group I (isoflurane)
Number of subjects: 82
Study: 18349060

Group type: EXPERIMENTAL
Intervention: Hyperthyroid (HR) subjects
Number of subjects: 16

Group type: COMPARATOR
Intervention: Euthyroid (EU) subjects
Number of subjects: 16
Study: 15558608

Group type: EXPERIMENTAL
Intervention: Hyperoxia (10% increase of baseline FiO2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hyperventilation (50% increase of ventilator cycling rate)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both hyperoxia and hyperventilation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham maneuver (control)
Number of subjects: 15
Study: 14618041

Group type: EXPERIMENTAL
Intervention: Bachmann's Bundle pacing
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Right atrial pacing
Number of subjects: 161

Group type: COMPARATOR
Intervention: Non-paced controls
Number of subjects: 161
Study: 11998040

Group type: EXPERIMENTAL
Intervention: Catheter-securing devices (specific devices not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional adhesive tape and pin device
Number of subjects: 0
Study: 8933665

Group type: EXPERIMENTAL
Intervention: Anti-pertussis vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feasibility study assessments
Number of subjects: 0
Study: 1540362

Group type: EXPERIMENTAL
Intervention: Labetalol (0.4 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (Labetalol and Placebo)
Number of subjects: 36
Study: 3546255

Group type: EXPERIMENTAL
Intervention: 100 mg oral meclofenamate during the follicular phase
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 100 mg oral meclofenamate during the luteal phase
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control) during the luteal phase
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.5 mg inhaled metaproterenol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 32
Study: 30883057

Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 552

Group type: COMPARATOR
Intervention: Delayed coronary angiography
Number of subjects: 552
Study: 29966858

Group type: COMPARATOR
Intervention: Response inhibition training using Go/No-go task, Stop Signal Task, and Collision Detection Task over five days.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Enhanced response inhibition training using Go/No-go and SST tasks with clearer performance feedback over 10 days.
Number of subjects: 65
Study: 26813208

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2400 IU/d)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study: 24355993

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Functional balance training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Education-only control
Number of subjects: 100
Study: 23174048

Group type: EXPERIMENTAL
Intervention: NMES facial device (20 min/day, 5 days/week)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 108
Study: 20078609

Group type: EXPERIMENTAL
Intervention: Sitaxentan 100 mg daily for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sitaxentan 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17686882

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E(2)) administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fulvestrant (pure antiestrogen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine/GHRP-2 stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E(2))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine/GHRH stimulation
Number of subjects: 0
Study: 16254541

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (promoting condoms and vaginal microbicides)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Basic intervention (promoting condoms and vaginal microbicides)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Perfect condom use (regardless of intervention arm)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Using a vaginal microbicide during > or =50% of acts of intercourse
Number of subjects: 427
Study: 11902371

Group type: EXPERIMENTAL
Intervention: Food Intake Recording Software System (FIRSSt)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dietitian-conducted 24-hour dietary recall (24hDR)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Hair sample as a bogus pipeline
Number of subjects: 138

Group type: COMPARATOR
Intervention: Observation of school lunch
Number of subjects: 138
Study: 10580458

Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5, 25, or 50 mg/d)
Number of subjects: 5435

Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen, diclofenac, nabumetone)
Number of subjects: 5435
Study: 7825523

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation (12 g fish oil)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Corn plus olive oil (control)
Number of subjects: 9
Study: 2328299

Group type: EXPERIMENTAL
Intervention: Diltiazem conventional tablet (2 x 30 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem slow-release capsule (120 mg SR)
Number of subjects: 24
Study: 438650

Group type: EXPERIMENTAL
Intervention: Bile acid mixture (cholic‐chenodeoxycholic 2:1, 20 mg/kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sitosterol-bile acid mixture (bile acid mixture plus sitosterols, 200 mg/kg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (pretreatment)
Number of subjects: 4
Study: 31837988

Group type: EXPERIMENTAL
Intervention: IC/IS + HR-cervix
Number of subjects: 46

Group type: COMPARATOR
Intervention: IC/IS
Number of subjects: 46
Study: 31045402

Group type: EXPERIMENTAL
Intervention: Ecologically based family therapy (EBFT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 183
Study: 28453843

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 184
Study: 25887789

Group type: EXPERIMENTAL
Intervention: Elective laparoscopic appendectomy plus maintenance treatment (5‐ASA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance 5‐ASA treatment (no appendectomy)
Number of subjects: 0
Study: 24462523

Group type: EXPERIMENTAL
Intervention: QRS normalization in leads V1 and V2 (n = 66 [18%])
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: New or increased R wave in leads V1‐V2 (n = 267 [71%])
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: QRS difference ≤ ‐25 ms
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Good substrate (low to moderate QRS score and LV activation time ≥110 ms)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Poor substrate and persistent LBBB QRS complex (absent BV fusion; QRS type 3: n = 42 [11%])
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Best BV QRS fusion pattern and greater reduction in electrical asynchrony (larger QRS difference)
Number of subjects: 375
Study: 22272985

Group type: EXPERIMENTAL
Intervention: Group Pedometer (GP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group Booklet (GB)
Number of subjects: 40
Study: 19338149

Group type: EXPERIMENTAL
Intervention: Shugan Liangxue Compound (SLC)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 17460329

Group type: EXPERIMENTAL
Intervention: Prior low-intensity exercise (E)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pasta meal
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bread meal
Number of subjects: 14

Group type: COMPARATOR
Intervention: No prior low-intensity exercise (NE)
Number of subjects: 14
Study: 15099874

Group type: EXPERIMENTAL
Intervention: Surgical termination of pregnancy with continuous ultrasound guidance
Number of subjects: 230
Study: 12492462

Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD)
Number of subjects: 31
Study: 9618624

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Enforcement intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 7730009

Group type: EXPERIMENTAL
Intervention: Nursing model implemented on Ward X (experimental ward)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control ward (Ward Y)
Number of subjects: 0
Study: 2497647

Group type: EXPERIMENTAL
Intervention: 2.5 cm capsule (12 mg of levonorgestrel)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 4.0 cm capsule (21.6 mg of levonorgestrel)
Number of subjects: 48
Study: 7293937

Group type: EXPERIMENTAL
Intervention: Whole eggs (0.5 cup, approximately 500 mg cholesterol)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cholesterol-free egg substitute
Number of subjects: 16
Study: 31606815

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with arthroplasty (ACDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with intervertebral cage (ACDF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without intervertebral cage (ACD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All surgical methods
Number of subjects: 0
Study: 30602311

Group type: EXPERIMENTAL
Intervention: Topical spironolactone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 28880750

Group type: EXPERIMENTAL
Intervention: Aqua-Lymphatic Therapy (ALT), group sessions twice a week for 6 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group, group sessions twice a week for 6 weeks
Number of subjects: 57
Study: 25541155

Group type: EXPERIMENTAL
Intervention: Docetaxel treatment
Number of subjects: 1031

Group type: COMPARATOR
Intervention: No PN (initially)
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Persistent PN
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Age >55, maximum grade of PN during docetaxel treatment, persistent muscle and joint pain, stomatitis, fatigue
Number of subjects: 1031
Study: 24081023

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg/week
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (10 pts with PHPT, no surgery indications)
Number of subjects: 24
Study: 21267745

Group type: EXPERIMENTAL
Intervention: Heat + O(3) (31°C + 70% rh + 0.10 ppm O(3))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (20°C + 50% rh)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control + O(3) (20°C + 50% rh + 0.10 ppm O(3))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heat (31°C + 70% rh)
Number of subjects: 10
Study: 19122354

Group type: COMPARATOR
Intervention: 1 mg overnight dexamethasone suppression test
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 mg overnight dexamethasone suppression test
Number of subjects: 100
Study: 18082216

Group type: EXPERIMENTAL
Intervention: Combination therapy (0.5 mg dutasteride + 0.4 mg tamsulosin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dutasteride (0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0
Study: 15154366

Group type: EXPERIMENTAL
Intervention: Nagipol (biologically active additive based on beer yeasts)
Number of subjects: 0
Study: 12364431

Group type: EXPERIMENTAL
Intervention: Oral Medroxyprogesterone Acetate (MPA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone (MP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vaginal Micronized Progesterone (MP)
Number of subjects: 28
Study: 9250122

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg elemental Zn daily for 6 months)
Number of subjects: 579
Study: 8099118

Group type: EXPERIMENTAL
Intervention: Dietary treatment based upon weight reduction and recommendations about a low alcohol intake
Number of subjects: 64

Group type: COMPARATOR
Intervention: Drug treatment using a stepped-care approach with atenolol as the first-choice drug
Number of subjects: 64
Study: 3828192

Group type: EXPERIMENTAL
Intervention: 12.5 mg i.v. prochlorperazine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 6.25 mg i.v. prochlorperazine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 25 mg oral prochlorperazine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11333010

Group type: EXPERIMENTAL
Intervention: Telmisartan (angiotensin II receptor antagonist)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 272
Study: 30648598

Group type: EXPERIMENTAL
Intervention: Oat noodles (100 g, replacing one or two meals/day for 10 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wheat noodles (placebo)
Number of subjects: 84
Study: 30145267

Group type: EXPERIMENTAL
Intervention: Standard rehabilitative care (physical and occupational therapy and psychoeducation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary and integrative health therapies (chiropractic, acupuncture, yoga and psychoeducation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative treatment (if initial treatment is not effective)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-stage treatment plus the alternative treatment (if initial treatment is not effective)
Number of subjects: 0
Study: 29383901

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guided peri-neural axillary plexus block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral nerve stimulation (PNS)
Number of subjects: 0
Study: 25332249

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy (doxorubicin and cyclophosphamide followed by paclitaxel)
Number of subjects: 4046
Study: 23038682

Group type: EXPERIMENTAL
Intervention: 7.47 g of intravenous methylprednisolone
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 4.98 g of intravenous methylprednisolone
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 2.25 g of intravenous methylprednisolone
Number of subjects: 159
Study: 20368410

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Caloric restriction
Number of subjects: 18
Study: 17376268

Group type: EXPERIMENTAL
Intervention: Thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (broad-spectrum antibiotics only)
Number of subjects: 42
Study: 15944096

Group type: EXPERIMENTAL
Intervention: Fibrin sealant applied prior to wound closure
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 81
Study: 11905433

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alcohol (social dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10027482

Group type: EXPERIMENTAL
Intervention: A.S. mouth wash (0.5% silver nitrate)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 137
Study: 7491366

Group type: EXPERIMENTAL
Intervention: Actovegin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2149688

Group type: EXPERIMENTAL
Intervention: Octreotide (400 micrograms per day via continuous subcutaneous infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 14
Study: 6992856

Group type: EXPERIMENTAL
Intervention: Topical oxytetracycline oily suspension, twice daily for 7 days each month for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral doxycycline 5 mg per kilogram of body weight, once a month for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received vitamin pills once a month
Number of subjects: 0